Sone-118 ((top)) -

William Shakespeare's Sonnet 118 is frequently analyzed as his "sickest" poem, using medical metaphors to argue that "bitter sauces" or emotional infidelity were a preventative measure against becoming sick of his beloved's "ne’er-cloying sweetness"

The concept of SONE-118 is deceptively simple: The Interview That Went Wrong . SONE-118

SONE-118 is an investigational small-molecule therapeutic reported as a selective antagonist of the thymic stromal lymphopoietin receptor (TSLPR) pathway, developed for immune-mediated inflammatory diseases. It targets signaling downstream of thymic stromal lymphopoietin (TSLP), a tissue-derived cytokine implicated in type 2 inflammation and barrier tissue immune activation (skin, airways, gut). By blocking TSLP-driven signaling, SONE-118 is intended to reduce the recruitment and activation of dendritic cells, type 2 innate lymphoid cells (ILC2s), Th2 T cells, and downstream eosinophilic and IgE-associated responses. William Shakespeare's Sonnet 118 is frequently analyzed as